Last reviewed · How we verify
C1-inhibitor
C1-inhibitor is a Small molecule drug developed by TSI, LLC. It is currently FDA-approved. Also known as: Cinryze.
C1-inhibitor is a protein that belongs to the serpin superfamily and functions as a plasma kallikrein inhibitor, regulating the contact system. It is used to treat conditions such as Hereditary Angioedema (HAE), Angioedema, and Bradykinin-mediated Angioedema, among others.
At a glance
| Generic name | C1-inhibitor |
|---|---|
| Also known as | Cinryze |
| Sponsor | TSI, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (PHASE3)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Complement and Graft-versus-host Disease (NA)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C1-inhibitor CI brief — competitive landscape report
- C1-inhibitor updates RSS · CI watch RSS
- TSI, LLC portfolio CI
Frequently asked questions about C1-inhibitor
What is C1-inhibitor?
Who makes C1-inhibitor?
Is C1-inhibitor also known as anything else?
What development phase is C1-inhibitor in?
Related
- Manufacturer: TSI, LLC — full pipeline
- Also known as: Cinryze
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing